BG108784A - Medicamentous form of propaphenone and process for the preparation thereof - Google Patents
Medicamentous form of propaphenone and process for the preparation thereofInfo
- Publication number
- BG108784A BG108784A BG108784A BG10878404A BG108784A BG 108784 A BG108784 A BG 108784A BG 108784 A BG108784 A BG 108784A BG 10878404 A BG10878404 A BG 10878404A BG 108784 A BG108784 A BG 108784A
- Authority
- BG
- Bulgaria
- Prior art keywords
- preparation
- propaphenon
- hydrochloride
- sodium glycolate
- medicamentous form
- Prior art date
Links
Abstract
The invention relates to an orally administered medicamentous form containing 1-Propanone, 1-[2-[2-hydroxy-3-(propylamino)-propoxy]phenyl]-3-phenyl-, hydrochloride known as propaphenon hydrochloride which is administered as anti-arrhythmic means in symptomatic and tachycardiac rhythm heart trouble and to a method for its preparation. The composition of the medicamentous form and the process for its preparation ensure the formation of tablet cores having excellent physicomechanical characteristics and degree of the propaphenon dissolution. The medicamentous form comprises propaphenon hydrochloride from 150 to 300 mg, two binders, copovidon from 5 to 10 wt.% and sodium glycolate starch from 2 to 6 wt.%, respectively of the mass of the tablet core, and fillers: microcrystalline cellulose, wheat starch and magnesium stearate. The process for its preparation includes the dry binding of the active substance with particle size distribution: 90% of sizes smaller than 35 micro m, 50% sizes smaller than 20 micro m with copovidon and subsequent formation of granulate mass by means of a granulation agent - aqueous gum of sodium glycolate starch, preferably sodium glycolate starch type A with viscosity higher than 40 mPa.s.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BG108784A BG65678B1 (en) | 2004-07-02 | 2004-07-02 | Drug formulation of propafenone and method of obtaining it |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BG108784A BG65678B1 (en) | 2004-07-02 | 2004-07-02 | Drug formulation of propafenone and method of obtaining it |
Publications (2)
Publication Number | Publication Date |
---|---|
BG108784A true BG108784A (en) | 2006-02-28 |
BG65678B1 BG65678B1 (en) | 2009-06-30 |
Family
ID=36999750
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BG108784A BG65678B1 (en) | 2004-07-02 | 2004-07-02 | Drug formulation of propafenone and method of obtaining it |
Country Status (1)
Country | Link |
---|---|
BG (1) | BG65678B1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010043950A3 (en) * | 2008-10-15 | 2010-12-02 | Aizant Drug Research Solutions Private Limited | Propafenone extended release composition |
-
2004
- 2004-07-02 BG BG108784A patent/BG65678B1/en unknown
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2010043950A3 (en) * | 2008-10-15 | 2010-12-02 | Aizant Drug Research Solutions Private Limited | Propafenone extended release composition |
Also Published As
Publication number | Publication date |
---|---|
BG65678B1 (en) | 2009-06-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5183470B2 (en) | Pharmaceutical composition containing levetiracetam and method for its preparation | |
HRP20200753T1 (en) | Pharmaceutical formulations containing dapagliflozin propylene glycol hydrate | |
CA2722093C (en) | Pharmaceutical compositions comprising brivaracetam | |
CA2470601A1 (en) | Co-processed carbohydrate system as a quick-dissolve matrix for solid dosage forms | |
CA2601955A1 (en) | Pharmaceutical composition comprising an omega-carboxyaryl substituted diphenyl urea for the treatment of cancer | |
JP2007518760A5 (en) | ||
JP2019505525A (en) | Pharmaceutical composition containing a JAK kinase inhibitor or a pharmaceutically acceptable salt thereof | |
RU2007137434A (en) | TABLETED MEDICINE WITH SLOW-RELEASED REMOVAL FOR VERTIGO | |
JP2014024874A (en) | Compressed preparation | |
EP1994926B9 (en) | Valsartan formulations | |
RU2002123182A (en) | CONTAINING IBUPROFEN COMPOSITION | |
WO2012136839A1 (en) | Dry formulation and pharmaceutical composition comprising fesoterodine or a salt or a solvate thereof | |
CN102846573B (en) | Silibinin double-layer slow-release tablets and preparation method thereof | |
JP5575114B2 (en) | Granules containing escitalopram oxalate | |
CN101332193B (en) | Preparation method of fluvoxamine maleate medicine composition | |
BG108784A (en) | Medicamentous form of propaphenone and process for the preparation thereof | |
EP1517683B1 (en) | Sustained release tablet containing indapamide | |
RU2463039C2 (en) | Escitalopram and hard pharmacetical composition containing it | |
CZ301299B6 (en) | Solid pharmaceutical composition with atorvastatin and telmisartan active ingredients | |
RU2251420C2 (en) | Ciprofloxacin-containing pharmaceutical composition and method for its obtaining | |
JPWO2004006945A1 (en) | Kampo extract-containing tablet composition and method for producing the same | |
CN106692149A (en) | Cariprazine medical oral preparation and preparation method thereof | |
CN104000821B (en) | Oral double-layer tablet containing telmisartan and amlodipine besylate and preparation method thereof | |
CN101103967B (en) | Medicine composition containing bevantolol hydrochloride | |
CA2531486A1 (en) | Saquinavir mesylate oral dosage form |